Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis

被引:0
作者
Jennie H. Best
Yuting Kuang
Yilin Jiang
Rajpal Singh
Andreas Karabis
Jennifer Uyei
Joseph Dang
William G. Reiss
机构
[1] Genentech,
[2] Inc.,undefined
[3] IQVIA,undefined
[4] Inc.,undefined
[5] IQVIA,undefined
[6] IQVIA,undefined
来源
Rheumatology and Therapy | 2021年 / 8卷
关键词
Disease activity score; Network meta-analysis; Remission; Rheumatoid arthritis; Targeted immune modulators;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:693 / 710
页数:17
相关论文
共 176 条
[1]  
Helmick CG(2008)Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheumatol 58 15-25
[2]  
Felson DT(2017)Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014 Rheumatol Int 37 1551-1557
[3]  
Lawrence RC(2010)Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007 Arthritis Rheumatol 62 1576-1582
[4]  
Hunter TM(2001)Rheumatoid arthritis Lancet (London, England) 358 903-911
[5]  
Boytsov NN(2016)2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Care Res 68 1-25
[6]  
Zhang X(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 79 685-699
[7]  
Schroeder K(2013)Therapies for active rheumatoid arthritis after methotrexate failure N Engl J Med 369 307-318
[8]  
Michaud K(2014)Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 66 775-782
[9]  
Araujo AB(2012)Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice Arthritis Care Res 64 640-647
[10]  
Myasoedova E(2019)Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial JAMA 322 315-325